OncoCyte Corporation
NASDAQ Global MarketRecent
price
P/E
ratio
div
yld
- -
ROIC.AI
Capital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- Similar Companies
- Business
- OncoCyte Corporation, rebranded as Insight Molecular Diagnostics Inc. in mid-2025 and relocated its headquarters to Nashville, Tennessee, is a molecular diagnostics company specializing in precision testing for cancer and transplant applications. The company’s core products include liquid biopsy tests for early cancer detection and monitoring, focusing primarily on lung cancer with tests such as DetermaRx, which identifies early-stage lung cancer patients at high risk for recurrence; DetermaIO, a gene expression test assessing tumor microenvironment to predict immunotherapy response; and a pipeline of tests including DetermaTx for tumor mutational status, DetermaCNI for blood-based cancer monitoring, and DetermaMx for long-term recurrence monitoring. Additionally, OncoCyte develops pharmaceutical services for molecular testing to support drug development and recently launched the GraftAssure research-use-only assay designed for organ transplant rejection monitoring. The company targets a broad addressable market including cancer diagnostics and a growing transplant rejection testing market estimated to exceed $1 billion globally. OncoCyte is advancing its GraftAssure test kit through FDA clearance via a Class II de novo pathway with expected commercialization in 2026, supported by clinical trial collaborations with several leading U.S. transplant centers and global hospitals. In 2024 and 2025, the company secured strategic partnerships including a notable investment and collaboration with Bio-Rad Laboratories, raised $57 million in equity funding, and expanded Medicare coverage for its VitaGraft Kidney test. These developments reflect its strategic business expansion and emphasis on regulatory progress and reimbursement pathways for new products. Founded in 2006 and headquartered originally in Irvine, California, OncoCyte operates primarily within the United States and globally through its clinical trial sites and pharmaceutical service collaborations. The company’s acquisition of molecular diagnostics firm Razor Genomics and prior acquisition of Chronix Biomedical have expanded its intellectual property portfolio and product capabilities, reinforcing its market position in cancer diagnostics and transplant rejection testing. Its ongoing clinical validation studies and FDA interactions underscore a significant operational focus on bringing innovations in molecular diagnostics to market in the near term.
Oncocyte Changes Name to Insight Molecular Diagnostics Inc. (iMDx), Moves Headquarters to Nashville
Medicare Boosts Reimbursement for Oncocyte's Flagship Technology
OncoCyte Corporation (OCX) Q1 2025 Earnings Call Transcript
Oncocyte Reports Q1 2025 Results and Business Progress
Oncocyte to Release First Quarter 2025 Results on May 12, 2025
Oncocyte to Release First Quarter 2025 Results on May 12, 2025
Best Momentum Stocks to Buy for May 6th
New Strong Buy Stocks for May 6th
Oncocyte Provides Positive Update on Clinical Trial Progress
Oncocyte's Proprietary Assay Demonstrates Long-Term Clinical Validity
New Strong Buy Stocks for April 24th
OncoCyte (OCX) Upgraded to Buy: What Does It Mean for the Stock?
Oncocyte to Participate in 24th Annual Needham Virtual Healthcare Conference
Oncocyte to Participate in 24th Annual Needham Virtual Healthcare Conference
OncoCyte Corporation (OCX) Q4 2024 Earnings Call Transcript
Oncocyte Reports Successful 2024; Sets Stage for 2025 Catalysts
Oncocyte Reports Successful 2024; Sets Stage for 2025 Catalysts
Oncocyte to Release Fourth Quarter 2024 Results on March 24, 2025
Oncocyte to Release Fourth Quarter 2024 Results on March 24, 2025
Oncocyte to Participate in BTIG MedTech, Digital Health, Life Science & Diagnostic Tools Conference